about
In vivo Magnetic Resonance Metabolic and Morphofunctional Fingerprints in Experimental Models of Human Ovarian CancerCholine Metabolism Alteration: A Focus on Ovarian CancerKey nodes of a microRNA network associated with the integrated mesenchymal subtype of high-grade serous ovarian cancerActivation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells.MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancerIL-27 induces the expression of IDO and PD-L1 in human cancer cells.Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer.Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer.Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopy.Cellular FLICE-inhibitory protein (c-FLIP) signalling: a key regulator of receptor-mediated apoptosis in physiologic context and in cancer.Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications.miRNA control of apoptotic programs: focus on ovarian cancer.CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation.The IL-18 antagonist IL-18-binding protein is produced in the human ovarian cancer microenvironment.Activated leukocyte cell adhesion molecule soluble form: a potential biomarker of epithelial ovarian cancer is increased in type II tumors.Characterisation of in vivo ovarian cancer models by quantitative 1H magnetic resonance spectroscopy and diffusion-weighted imaging.Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment.CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma.Phosphatidylcholine-specific phospholipase C inhibition reduces HER2-overexpression, cell proliferation and in vivo tumor growth in a highly tumorigenic ovarian cancer model.Clinicopathological impact of ABCC1/MRP1 and ABCC4/MRP4 in epithelial ovarian carcinoma.A miRNA signature assessing ovarian cancer prognosis.Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients.Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies.c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome.Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer.Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.Simultaneous E-cadherin and PLEKHA7 expression negatively affects E-cadherin/EGFR mediated ovarian cancer cell growth.Integration of MRI and MRS approaches to monitor molecular imaging and metabolomic effects of trabectedin on a preclinical ovarian cancer modelGenomic Landscape of Ovarian CancerSubcellular Localization of Activated Leukocyte Cell Adhesion Molecule Is a Molecular Predictor of Survival in Ovarian Carcinoma PatientsOne-Carbon Metabolism: Biological Players in Epithelial Ovarian CancerGynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions
P50
Q26742109-BB698480-B623-4DFA-ADBA-70CCC53679A4Q26742116-1F1F9E77-8381-4152-AE44-7B911A0498DEQ28082679-18CAF22C-D57E-401D-8DF8-756CAF100F9AQ33699139-D83ADE7D-0828-4992-ACDA-5104F71F00A4Q34718013-4BC5D632-B7BD-4BEE-AE69-60764703598BQ36685395-1A56024F-5910-4D21-9AE3-94436BE76105Q36870100-2AEBAA52-1717-46B4-B2FF-449FA71AFA55Q37507405-D3E25CCE-AC01-4AD2-8E97-4CC89F5668BBQ37559012-D70FB897-62DD-47BA-89C1-6CA1BB9F43D1Q37637257-F9CD1B3D-B90D-4548-930A-5D6AFF7FD09EQ37662851-E60F9E5C-93D3-4703-9ACE-928F5B27BE2FQ37861225-870260F0-5B29-49F1-870A-37E1BAECD43AQ38639827-B30B60EC-3FE7-494D-BEA0-51BA454022B7Q39122547-AAAE33EB-E291-48F6-BFF4-07EB65008E12Q39241466-28700830-374C-4D30-A3BF-A391A43EBE01Q39454124-5976391A-C885-486A-AB7E-B34C4A799658Q40169753-6136EBC6-3DD0-4FEB-908F-5E34D29C2B5FQ40527978-88AF85D2-DE19-482E-B34C-18B8A4C6D9FBQ41549845-605FD5ED-44A9-4D09-B4F1-B4B7065FC028Q41811277-3C58F572-0288-4103-8E7E-B599B7AC0A0EQ42330446-A9BCA43B-2CCF-45CE-8B1C-AB8082744F95Q42343235-7B274733-2C07-4EF0-BC9E-84118FA03C43Q44459409-ECD364D3-F8AE-430F-9B85-F545895448BDQ45354826-2022AA22-2C75-4F22-B164-4156D1AF3453Q45850707-0DEC489E-09B9-4D81-A59E-5F8C815373FAQ52860239-193A0D34-5658-40B5-81A1-292EF334B691Q55624634-7F5C2586-1DF8-4F31-9863-C2EEB6D64851Q58097975-74BD7F56-C937-4155-97C4-D2A58F96DFE4Q58813264-3A60F7F4-E21D-43DD-BBC1-4CD8C3BBFD24Q58813345-781B23D6-5B76-4737-85AA-24F19E0CA882Q59134002-B0472A2C-A8CE-4FB7-93E2-0F5963131814Q64099682-C7987D0E-1A3F-4F0E-8A34-AF7B22F4C733
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marina Bagnoli
@ast
Marina Bagnoli
@en
Marina Bagnoli
@es
Marina Bagnoli
@nl
Marina Bagnoli
@sl
type
label
Marina Bagnoli
@ast
Marina Bagnoli
@en
Marina Bagnoli
@es
Marina Bagnoli
@nl
Marina Bagnoli
@sl
prefLabel
Marina Bagnoli
@ast
Marina Bagnoli
@en
Marina Bagnoli
@es
Marina Bagnoli
@nl
Marina Bagnoli
@sl
P106
P1153
7003400535
P21
P31
P496
0000-0001-7655-4630